Improving Capital Productivity Through the Sale of Strategically Held Shares
First written in FY2021. 5 of 8 entries say "Advanced", first in FY2022. Latest entry: FY2026.
- FY2026Increase in holdings and continued salesAnnual report
「By the end of March 2027, the final year of the “2027 MEDIPAL Medium-Term Vision: Change the 卸 Forever—Continuous Transformation,” we plan to reduce the balance of holdings (¥96.7 billion as of the end of March 2026) to 10% or less of net assets and to ¥50 billion or less.」
Although 9 strategic shareholdings were sold, the balance of holdings was ¥96.7 billion at the end of March 2026. The policy of reducing the balance to ¥50 billion or less, among other targets, by the end of March 2027 remains in place. - 2026-05-25AdvancedGeneral Meetings of Shareholders
「Regarding the status of holdings of policy-oriented shares, the balance stood at ¥96.7 billion as of the end of March 2026. As a result of selling policy-oriented shares, the number of holdings declined to 62, and their ratio to net assets fell to 12.2%.」
The disclosure quantified progress in reducing policy-oriented shareholdings by reporting the balance, number of holdings and ratio to net assets as of the end of March 2026. - FY2025AdvancedAnnual report
「By the end of March 2027, the final year of the “2027 MEDIPAL Medium-Term Vision: Change the 卸 Forever—Continuous Transformation,” we plan to reduce the balance of holdings (¥95.4 billion as of the end of March 2025) to 10% or less of net assets and to ¥50 billion or less.」
The balance of strategic shareholdings was ¥95.4 billion at the end of March 2025. The policy of reducing the balance to 10% or less of net assets and to ¥50 billion or less by the end of March 2027 remains in place. - FY2025-H1AdvancedAnnual report
「The sale of strategic investment shares resulted in ¥4.912 billion being recorded as extraordinary income. This offset the impact of the recording of ¥1.944 billion in compensation received in connection with the relocation of the head office and ¥1.253 billion in gain on step acquisitions arising from the conversion of 東七株式会社 into a subsidiary in the same period of the previous year, resulting in an ¥1.153 billion increase in extraordinary income and expenses.」
The sale of strategic investment shares resulted in ¥4.912 billion in extraordinary income. The sale in line with the policy of reducing strategic shareholdings was also recorded for the interim consolidated accounting period. - FY2024Increase in holdings and continued salesAnnual report
「By the end of March 2027, the final year of the “2027 MEDIPAL Medium-Term Vision: Change the 卸 Forever—Continuous Transformation,” we plan to reduce the balance of holdings (¥100.8 billion as of the end of March 2024) to 10% or less of net assets and to ¥50 billion or less.」
The balance of strategic shareholdings was ¥100.8 billion at the end of March 2024. Although 3 holdings were sold, the policy of reducing the balance to 10% or less of net assets and to ¥50 billion or less by the end of March 2027 remains in place. - FY2023AdvancedAnnual report
「By the end of March 2027, the final year of the “2027 MEDIPAL Medium-Term Vision: Change the 卸 Forever—Relentless Transformation,” the company plans to reduce its holdings balance (¥96.7 billion as of the end of March 2023) to no more than 10% of net assets and no more than ¥50 billion.」
Regarding cross-shareholdings, the company specified a policy of reducing the holdings balance to no more than 10% of net assets and no more than ¥50 billion by the end of March 2027. During the fiscal year, it sold shares in 2 unlisted companies and 9 listed companies. - FY2022AdvancedAnnual report
「Regarding its cross-shareholdings, the company sold shares in 18 companies after considering the purpose and economic rationale for holding them. It will continue to consider whether to retain such holdings with a view to improving capital productivity.」
The sale of cross-shareholdings expanded from 7 companies in the previous disclosure to 18, advancing reductions aimed at improving capital productivity. - FY2021First statedAnnual report
「Regarding its cross-shareholdings, the company sold shares in 7 companies after considering the purpose and economic rationale for holding them. It will continue to consider whether to retain such holdings with a view to improving capital productivity.」
The company sold cross-shareholdings in 7 companies and indicated a policy of considering whether to continue holding them with a view to improving capital productivity.